CTTN

Src substrate cortactin · Q14247 · CTTN on Sugi Atlas →

0 patent compounds predicted against CTTN, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to CTTN by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Phase II Dasatinib Study in Advanced Breast Cancer PHASE2COMPLETED
AZD0530 to Treat Recurrent Stage IIIB/IV NSCLC Previously Treated With Combination Chemotherapy PHASE2COMPLETED
Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer PHASE2COMPLETED
Doxycycline in Human Pulmonary Tuberculosis PHASE2COMPLETED
Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction PHASE2COMPLETED
Imatinib in Dermatofibrosarcoma Protuberans (DFSP) PHASE1/PHASE2COMPLETED
Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery PHASE2COMPLETED
Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia PHASE2COMPLETED
First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALL PHASE2COMPLETED
Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma PHASE2COMPLETED
Trial of Dasatinib in Advanced Sarcomas PHASE2COMPLETED
SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme PHASE2UNKNOWN
FAK Inhibitor in Patients With Advanced Solid Tumors PHASE1NOT_YET_RECRUITING
KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment PHASE1COMPLETED
Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors PHASE1COMPLETED
FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
F01 in the Treatment of Relapsed/Refractory Non-hodgkin's Lymphoma PHASE1UNKNOWN
Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer EARLY_PHASE1COMPLETED
The Role of Stromal Cell-Derived Factor-1 (SDF-1)/CXC Chemokine Receptor 4 (CXCR4) in Metastasis of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma nanUNKNOWN
The Roles of Neutrophil Elastase in Lung Cancer nanUNKNOWN
Safety and Efficacy of Combination Acthar Gel and Tacrolimus in the Treatment of Steroid Resistant Nephrotic Syndrome nanSUSPENDED
Pulsed Electro Magnetic Fields (PEMF) in Depression nanCOMPLETED
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia nanUNKNOWN
Blood-based Biomarkers for the Prognosis of Sports Related Concussion nanCOMPLETED
Immune Cell Response to Stimuli nanRECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Evaluation of a New Approach of the Diagnosis of Constitutional Functional Disorders of Platelets nanCOMPLETED
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development nanCOMPLETED
Predictive Value of E-cadherin, β-catenin and SOX4 in Recurrence and/or Progression of Non-muscle Invasive Urinary Bladder Transitional Cell Carcinoma. A Retrospective Study nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CTTN binder may also engage these)

ProteinNameSimilarity
Q01406 1.000 Q01406 →
Q66HL2 1.000 Q66HL2 →
Q60598 1.000 Q60598 →
P49710 0.996 P49710 →
HCLS1 Hematopoietic lineage cell-specific protein 0.992 landscape →
Q9DC07 0.982 Q9DC07 →
Q8CHU3 0.982 Q8CHU3 →
Q9Z1Z3 0.982 Q9Z1Z3 →
Q61792 0.981 Q61792 →
Q5R5W0 0.980 Q5R5W0 →
O77506 0.979 O77506 →
Q99MZ8 0.979 Q99MZ8 →
Q4QQU6 0.979 Q4QQU6 →
Q0II04 0.979 Q0II04 →
Q7TPW1 0.979 Q7TPW1 →
LASP1 LIM and SH3 domain protein 1 0.979 landscape →
Q3T045 0.978 Q3T045 →
Q2QQ99 0.978 Q2QQ99 →
O75940 0.978 O75940 →
O48713 0.978 O48713 →
Q9ERA6 0.978 Q9ERA6 →
Q5R591 0.978 Q5R591 →
Q8CH02 0.977 Q8CH02 →
Q28C44 0.977 Q28C44 →
Q99KN9 0.977 Q99KN9 →
Q15417 0.977 Q15417 →
Q6DEY1 0.977 Q6DEY1 →
Q3B7M5 0.977 Q3B7M5 →
Q32NW2 0.977 Q32NW2 →
Q9GK38 0.977 Q9GK38 →